Ann Tsukamoto

Ann Tsukamoto (born July 6, 1952 California, United States) is an inventor, scientist and stem cell researcher. In 1991, Tsukamoto and her colleagues Charles Baum, Irving Weissman, Anne-Marie Buckle, and Bruno Peault became the first researchers to identify and isolate blood-forming stem cells.[1][2] As a result of her research bone marrow transplants have saved the lives of thousands of people battling blood cancer. She has since devoted her life to researching and developing stem cell medicines and continues to work to save lives as the Executive Vice President of Scientific and Strategic Alliances at StemCells Inc.

Ann Tsukamoto
Born6 July 1952
Alma materUniversity of California, San Diego

University of California, Los Angeles

Scientific career
FieldsStem cell biology
InstitutionsSyStemix StemCells inc.

Tsukamoto is a co-patentee for the isolation process of the human blood stem cell. In 1991 the patent was awarded.[3]

Early life and education

Ann Tsukamoto received her undergraduate from University of California, San Diego and later received her Ph.D.from University of California, Los Angeles.[4]

Career

Academic research

She did her post doctoral research at the University of California, San Francisco where she worked alongside Nobel Laureate Harold Varmus. Together they created a transgenic model for breast cancer.[4]

Industrial research

Tsukamoto was employed at SyStemix, a biotechnology company, from 1989-1997 where she was connected with isolation of the hematopoietic stem cell.[4] In 1998, she joined StemCells, Inc. where she became a leader in overseeing the isolation of human liver and neural stem cells to a variety of different diseases. When she joined the company, she was one of the few first world class researchers who were focused on the development and discovery of human stem cells. During her time at StemCells, Dr. Tsukamoto led the scientific team that discovered the human central nervous system stem cell (HuCNS-SC®).[5] With her colleagues, they were to identify and isolate blood-forming stem cells. She has received multiple leadership roles while employed with Stem Cells, Inc.

Tsukamoto holds 12 patents related to her research.[6]

gollark: Also, if you've ever seen genetic algorithms, you'll know that they will ruthlessly exploit any quirk of the fitness functions.
gollark: And how do you work out exactly what the evaluator is to count as "harming humans"?
gollark: But you have to define a fitness function.
gollark: Suspiciously human AI.
gollark: Yes, lots of scifi authors and such seemed to assume that we would get suspiciously human AI before, well, computery computers. Probably they just didn't think of the second possibility/

References
  1. "A Patient talks about being treated in a landmark breast cancer clinical trial more than a dozen years ago". Institute for Stem Cell Biology
    and Regenerative Medicine    . Retrieved 2018-10-06.
  2. Bellis, Mary. "Ann Tsukamoto - The Stem Cell Research of Ann Tsukamoto". theinventors.org. Retrieved 2018-03-30.
  3. "Ann Tsukamoto - The Stem Cell Research of Ann Tsukamoto". theinventors.org. Retrieved 2019-11-19.
  4. "BIOS 206 Brief Speaker Biographies" (PDF). Stanford.edu.
  5. National Academies of Sciences, Engineering; Division, Health and Medicine; Policy, Board on Health Sciences; Medicine, Forum on Regenerative (2017-03-15). Speaker Biographical Sketches. National Academies Press (US).
  6. "Ann Tsukamoto Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2018-03-31.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.